# Celltrion Omlyclo European market expansion

> Live situation record from CLSTR: https://clstr.news/situations/celltrion-omlyclo-european-market-expansion
> Updated: 2026-09-09T23:18:24.000Z. Sources: 6. Developments: 2.

Celltrion has expanded the availability of Omlyclo, its omaliizumab biosimilar for allergic asthma and chronic spontaneous urticaria, across major European markets. Following the initial release of 75mg and 150mg doses, the company launched a 300mg single-dose option in Germany, the United Kingdom, and France to improve patient convenience through single-injection administration.

The product is available in pre-filled syringes and auto-injectors, featuring enhanced stability that allows for a two-year refrigerated shelf life and a ‘re-refrigeration’ capability after room-temperature exposure. 

As of July 2026, the biosimilar has seen significant commercial success in Southern Europe, achieving a market share exceeding 90% in Spain and surpassing initial sales targets in Italy. Celltrion is currently working to expand its presence across 26 European countries by participating in national tenders and strengthening direct sales networks with medical institutions.

## Claims

- Omlyclo is currently being sold in 26 European countries. (corroborated by 3 sources)
- Omlyclo's market share in Spain exceeded 90% as of July. (corroborated by 3 sources)
- Sales in Italy have exceeded initial business targets. (corroborated by 3 sources)
- Omlyclo is available in 75mg, 150mg, and 300mg dosages. (corroborated by 3 sources)
- Celltrion participated in the European Respiratory Society Congress in Barcelona. (corroborated by 3 sources)
- The product is offered via pre-filled syringes and auto-injectors. (corroborated by 2 sources)
- Omlyclo is a biosimilar of Xolair used for allergic asthma and chronic spontaneous urticaria. (corroborated by 2 sources)
- Celltrion plans to participate in the Global Urticaria Forum 2026 in Berlin. (corroborated by 2 sources)

## Timeline

### 2026-09-09: Celltrion's Omlyclo expands in Europe with 90% market share in Spain

Celltrion's omaliizumab biosimilar, Omlyclo, has achieved over 90% market share in Spain and exceeded sales targets in Italy as it expands across 26 European countries.

4 sources. https://clstr.news/cluster/celltrions-omlyclo-expands-in-europe-with-90-market-share-in-spain

### 2026-08-24: Celltrion launches 300mg Omlyclo biosimilar in Europe

Celltrion has launched its 300mg Omlyclo biosimilar in major European markets, offering improved dosing convenience and enhanced storage stability compared to the original medication.

4 sources. https://clstr.news/cluster/celltrion-launches-300mg-omlyclo-biosimilar-in-europe

---
Cite as: Celltrion Omlyclo European market expansion. CLSTR, https://clstr.news/situations/celltrion-omlyclo-european-market-expansion